Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Hepatocellular 27Parkinson Disease 4, Autosomal Dominant Lewy Body 24Neoplasms 14Melanoma 9Endometrial Neoplasms 8Carcinoma, Renal Cell 7Carcinoma, Non-Small-Cell Lung 7Thyroid Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Cholangiocarcinoma 6Stomach Neoplasms 4Recurrence 4Carcinoma 4Biliary Tract Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Paraganglioma, Extra-Adrenal 2Osteosarcoma 2Neuroendocrine Tumors 2Lung Neoplasms 2Liver Neoplasms 2Glioma 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid cancer, Hurthle cell 1

Interventions

Cyclophosphamide 125Peripheral Blood Stem Cell Transplantation 84fludarabine phosphate 81Etoposide 73Filgrastim 64Mycophenolic Acid 63Tacrolimus 57Whole-Body Irradiation 55Busulfan 52Doxorubicin 50Radiotherapy 48Melphalan 48Cyclosporine 47Brentuximab Vedotin 45Rituximab 39Vinblastine 37fludarabine 36Granulocyte Colony-Stimulating Factor 36Antilymphocyte Serum 35Prednisone 33Methotrexate 32Vincristine 31Gemcitabine 30Dacarbazine 29Bleomycin 29Cytarabine 26Carmustine 22Bendamustine Hydrochloride 21Sirolimus 18Ifosfamide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hodgkin Disease × lenvatinib × Clear all
NCT00121719 2023-06-22

An Open Label Dose Escalation Study Of E7080

Eisai Inc.

Phase 1 Completed
82 enrolled 34 charts
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡